38.01Open22.50Pre Close1 Volume24 Open Interest310.00Strike Price3.80KTurnover80.56%IV4.22%PremiumMay 16, 2025Expiry Date23.91Intrinsic Value100Multiplier15DDays to Expiry14.10Extrinsic Value100Contract SizeAmericanOptions Type0.7051Delta0.0062Gamma9.33Leverage Ratio-0.6444Theta0.0857Rho6.58Eff Leverage0.2386Vega
Madrigal Pharmaceuticals Stock Discussion
Can Madrigal's Rezdiffra Breakthrough in Cirrhosis Patients Transform Liver Disease Treatment?
📊⚡️📊
MDGL gained as much as 15.2% to a $294.44 intraday high after Wolfe lauded the company's breakthrough liver drug Rezdiffra, according to published reports.
The U.S. Food and Drug Administration approved Rezdiffra in March as the first treatment fornonalcoholic steatoh...
» Holdings in Top 20: 58.46%
» Qtr over Qtr Change**: 28.47%
Top Holdings:
$Cerevel Therapeutics Holdings (CERE.US)$
$Amicus Therapeutics (FOLD.US)$
$Iovance Biotherapeutics (IOVA.US)$
$Arcellx (ACLX.US)$
$Nuvalent (NUVL.US)$
$Apogee Therapeutics (APGE.US)$
$Inhibrx (INBX.US)$
$Fusion Pharmaceuticals (FUSN.US)$
$Rhythm Pharmaceuticals (RYTM.US)$
$Vaxcyte (PCVX.US)$
$Soleno Therapeutics (SLNO.US)$
$Medtronic (MDT.US)$
$Madrigal Pharmaceuticals (MDGL.US)$